Literature DB >> 18393131

The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses.

A Babinska1, K Sworczak, P Wisniewski, A Nałecz, K Jaskiewicz.   

Abstract

BACKGROUND: The detectability of adrenal incidentalomas (incidentally found adrenal tumours) in the whole population is estimated at 0.1%; 0.42% in non-endocrine patients and at 4.3% in oncologically diagnosed ones. Even up to 16% of incidentalomas of adrenal glands can be malignant lesions. The issue of crucial importance is the histopathological differentiation between benign lesions and malignant tumours of the adrenal cortex and medulla.
OBJECTIVES: To evaluate whether the immunohistochemical analysis of the expression of p53, p21, PCNA and Ki67 in the tumour's tissue can be useful in the histopathological diagnostics of adrenal incidentalomas and whether it is important for prognosis.
MATERIAL AND METHODS: Our series consisted of 74 tumour samples from 164 patients operated for incidentalomas. There were 43 cortical adenomas, 11 cortical adrenocarcinomas and 20 PHEOs (including 5 malignant lesions). Using monoclonal antibodies, the expression of p53, p21, PCNA and Ki67 was evaluated.
RESULTS: We found a statistically significant correlation between the expression of p53, p21, Ki67 and the differential diagnosis of adrenal cortical adenoma and adrenocortical carcinoma (for proteins: p53 p=0.010, for p21 p=0.010, for Ki67 p<0.001). The statistical significant correlation between PCNA protein and diagnosis of adrenal cortical adenoma and adrenocortical carcinoma was not found. The statistically significant correlation between p21, PCNA proteins and the diagnosis of benign and malignant PHEOs was not estimated. There was no expression of Ki67 or p53 protein above the assumed level in benign and malignant pheochromocytomas. The statistically significant correlation between p53, p21, PCNA or Ki67 and the occurrence of metastases in adrenocarcinoma and malignant PHEOs was not found.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393131     DOI: 10.1055/s-2007-993164

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  5 in total

Review 1.  What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics.

Authors:  C Christofer Juhlin; Ozgur Mete; Jérôme Bertherat; Thomas J Giordano; Gary D Hammer; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2021-02-03       Impact factor: 3.943

2.  MicroRNA-149-3p expression correlates with outcomes of adrenocortical tumor patients and affects proliferation and cell cycle progression of H295A adrenocortical cancer cell line.

Authors:  Keteryne Rodrigues da Silva; Luciana Chain Veronez; Carolina Alves Pereira Correa; Régia Caroline Peixoto Lira; Mirella Baroni; Rosane de Paula Silva Queiroz; Sonir Roberto Rauber Antonini; José Andres Yunes; Silvia Regina Brandalise; Luiz Gonzaga Tone; Carlos Alberto Scrideli
Journal:  Hum Cell       Date:  2022-09-02       Impact factor: 4.374

3.  [Diagnostic pitfalls with Cushing's syndrome].

Authors:  W Hunger-Battefeld; M Gajda; A Hansch; A Mandecka; U A Müller; G Wolf
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743

4.  Hormonal activity in clinically silent adrenal incidentalomas.

Authors:  Anna Babińska; Małgorzata Siekierska-Hellmann; Krzysztof Błaut; Anna Lewczuk; Piotr Wiśniewski; Maria Gnacińska; Lukasz Obołończyk; Renata Swiątkowska-Stodulska; Krzysztof Sworczak
Journal:  Arch Med Sci       Date:  2012-02-29       Impact factor: 3.318

Review 5.  Cellular Senescence in Adrenocortical Biology and Its Disorders.

Authors:  Xin Gao; Faping Li; Bin Liu; Yuxiong Wang; Yishu Wang; Honglan Zhou
Journal:  Cells       Date:  2021-12-09       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.